Chronic Lymphocytic Leukemia trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Chronic Lymphocytic Leukemia. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month8 studies across 5 companies, in the next 180 days.
November 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | National Acalabrutinib Observational StudyNCT05437250observationalTime to Discontinuation | — | Active, not recruiting | 2026-11-15 | in 87 d | 2026-05-28 |
| ABBV | AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)NCT04895436Overall response (OR) in Cohort 1 after end of combination treatment | Phase 2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-02-09 |
| ONC | BeOne Medicines | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-19 |
| ONC | BeOne Medicines | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-09 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AAPG | Ascentage Pharma Group Inc. | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467Objective Response Rate (ORR) | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-03-27 |
| AAPG | Ascentage Pharma Group Inc. | Global Trial in APG2575 for Patients With CLL/SLLNCT06104566PFS | Phase 3 | Recruiting | 2026-12-31 | in 133 d | 2026-06-18 |
| AZN | AstraZeneca | AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseNCT06548152observationalTo measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months | — | Recruiting | 2026-12-31 | in 133 d | 2026-07-13 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Chronic Lymphocytic Leukemia
most recently updated first166 studies match. Showing the first 100 of 166 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | $457.5B | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT02966756Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 66 | 2017-10-12 | Dec 2030 | ≤ 1,594 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | 2021-09-13 | Nov 2026 | ≤ 102 d | 2026-08-19 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC) | Phase 2 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 100 | 2025-10-15 | Jan 2028 | ≤ 529 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaNCT07277231Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC) | Phase 3 | Recruiting | Drug: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax | Chronic Lymphocytic Leukemia | 500 | 2026-01-22 | Feb 2031 | ≤ 1,653 d | 2026-08-19 |
| ABBV | AbbVie | $457.5B | Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingNCT03342144observationalPercentage of Participants Achieving Best Overall Response Rate (ORR) | — | Recruiting | — | Chronic Lymphocytic Leukemia (CLL) | 500 | 2017-12-04 | Dec 2030 | ≤ 1,594 d | 2026-08-14 |
| AZN | AstraZeneca | — | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureNCT06651970Safety endpoints 1: To evaluate the incidence of CV (CardioVascular) adverse events leading to drug discontinuation after acalabrutinib treatment compared to investigators choice of treatment. | Phase 4 | Recruiting | Drug: Acalabrutinib · Other: Investigator's choice of treatment | Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | 60 | 2025-02-04 | 2030-08-16 | in 1,457 d | 2026-08-14 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06980116Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: EXS73565 | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM) | 85 | 2025-03-31 | Jun 2028 | ≤ 680 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesNCT06564038Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest | Phase 1/2 | Recruiting | Drug: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma | 408 | 2025-01-30 | 2029-06-11 | in 1,026 d | 2026-08-12 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.NCT06697184Number of Participants who Experience Tumor Lysis Syndrome (TLS) | Phase 1/2 | Recruiting | Drug: Sonrotoclax, Zanubrutinib | Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL | 258 | 2025-01-23 | 2029-11-30 | in 1,198 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)NCT06943872Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D | Phase 3 | Recruiting | Drug: Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 630 | 2025-06-11 | 2029-09-30 | in 1,137 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsNCT06970743Progression-Free Survival (PFS) by IRC | Phase 3 | Active, not recruiting | Drug: BGB-16673, Bendamustine, Rituximab, Methylprednisolone, Chlorambucil, Obinutuzumab | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 153 | 2025-05-29 | 2029-11-30 | in 1,198 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)NCT06073821Cohort 1: Progression Free Survival (PFS） | Phase 3 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib, Venetoclax, Obinutuzumab | CLL | 652 | 2023-11-11 | Feb 2032 | ≤ 2,019 d | 2026-08-07 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsNCT06846671Progression-Free Survival (PFS) by Independent Review Committee (IRC) | Phase 3 | Recruiting | Drug: BGB-16673, Bendamustine, Idelalisib, Rituximab, Venetoclax | CLL, Chronic Lymphocytic Leukemia | 250 | 2025-04-10 | 2028-05-15 | in 634 d | 2026-08-07 |
| ONC | BeOne Medicines | $545.6B | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT06973187Progression-Free Survival (PFS) per Independent Review Committee (IRC) | Phase 3 | Recruiting | Drug: BGB-16673, Pirtobrutinib | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 500 | 2025-09-04 | 2028-04-17 | in 606 d | 2026-08-06 |
| AZN | AstraZeneca | — | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabNCT07024706Overall Response Rate (ORR) | Phase 2 | Recruiting | Drug: Acalabrutinib, Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 80 | 2026-06-04 | 2029-05-01 | in 985 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT07218341Percentage of Participants with a Grade 3 or Higher Treatment-emergent Adverse Events (AEs) | Phase 4 | Recruiting | Drug: Pirtobrutinib, Idelalisib | Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | 150 | 2026-03-09 | May 2030 | ≤ 1,380 d | 2026-08-06 |
| AZN | AstraZeneca | — | PICAROS - Acalabrutinib RWE on 1L CLL in SpainNCT05999877observationalProportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1). | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 192 | 2023-07-11 | 2029-03-31 | in 954 d | 2026-08-04 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456Progress Free Survival (PFS) | Phase 3 | Recruiting | Drug: Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | CLL/SLL | 344 | 2024-04-07 | Aug 2027 | ≤ 376 d | 2026-07-28 |
| AZN | AstraZeneca | — | ALICIA (Acalabrutinib in CLL Therapy)NCT04746950observational• progression-free survival (rwPFS) in patients with CLL who are treated with acalabrutinib in clinical practice in Russia | — | Completed | — | Chronic Lymphocytic Leukemia | 90 | 2021-02-03 | 2026-02-28actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | Study of Oral LOXO-338 in Patients With Advanced Blood CancersNCT05024045Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338 | Phase 1 | Completed | Drug: LOXO-338, Pirtobrutinib | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell | 27 | 2021-09-30 | 2023-06-14actual | — | 2026-07-17 |
| AZN | AstraZeneca | — | Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusNCT07288515observationalTime to treatment discontinuation | — | Recruiting | — | Chronic Lymphocytic Leukemia | 50 | 2025-12-31 | 2029-12-31 | in 1,229 d | 2026-07-16 |
| AZN | AstraZeneca | — | AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseNCT06548152observationalTo measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months | — | Recruiting | — | Chronic Lymphocytic Leukemia | 120 | 2025-04-28 | 2026-12-31 | in 133 d | 2026-07-13 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate | Phase 2 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib | Chronic Lymphocytic Leukemia | 94 | 2024-11-14 | Nov 2026 | ≤ 102 d | 2026-07-09 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | 572 | 2022-04-13 | Jan 2027 | ≤ 164 d | 2026-07-02 |
| AAPG | Ascentage Pharma Group Inc. | — | Global Trial in APG2575 for Patients With CLL/SLLNCT06104566PFS | Phase 3 | Recruiting | Drug: lisaftoclax +BTK inhibitor, BTK inhibitor | CLL/SLL | 400 | 2023-12-20 | 2026-12-31 | in 133 d | 2026-06-18 |
| AZN | AstraZeneca | — | REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaNCT06170671observationalTime to acalabrutinib treatment discontinuation (TTD) | — | Active, not recruiting | Drug: Non interventional study | Chronic Lymphocytic Leukemia | 250 | 2023-12-13 | 2028-09-30 | in 772 d | 2026-06-18 |
| CRIS | Curis, Inc. | $22M | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNCT07271667Cohort 1: Undetectable Measurable Residual Disease (uMRD) Rate | Phase 2 | Recruiting | Drug: Emavusertib, Zanubrutinib | Chronic Lymphocytic Leukemia, B-cell Malignancies | 108 | 2026-04-23 | Nov 2027 | ≤ 467 d | 2026-06-12 |
| AZN | AstraZeneca | — | National Acalabrutinib Observational StudyNCT05437250observationalTime to Discontinuation | — | Active, not recruiting | Drug: Non interventional study | Chronic Lymphocytic Leukemia | 350 | 2022-09-13 | 2026-11-15 | in 87 d | 2026-05-28 |
| AZN | AstraZeneca | — | CLL Therapy Approaches in RussiaNCT05140369observationalSex | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 6,000 | 2021-10-29 | 2027-03-31 | in 223 d | 2026-05-14 |
| ABBV | AbbVie | $457.5B | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialNCT03844048Number of Participants With Adverse Events | Phase 3 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer | 165 | 2019-09-06 | Aug 2027 | ≤ 376 d | 2026-05-13 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsNCT05618028Number of Participants With Adverse Events (AE) | Phase 1 | Active, not recruiting | Drug: ABBV-525 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma | 78 | 2023-04-04 | Jul 2029 | ≤ 1,076 d | 2026-05-04 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNCT03913949Maximum Tolerated Dose (MTD) | Phase 1 | Active, not recruiting | Drug: APG-2575 | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 74 | 2019-06-03 | 2024-10-20actual | — | 2026-05-01 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainNCT06125795observationalChange in Participant Functioning Measured Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the EORTC Chronic Lymphocytic Leukemia 17 (EORTC-CLL17) Supplement | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 146 | 2023-11-06 | Jul 2026 | — | 2026-05-01 |
| AZN | AstraZeneca | — | Acalabrutinib Real World Italian obSErvational Study -ARISENCT06205498observationaltime to acalabrutinib discontinuation | — | Active, not recruiting | Drug: acalabrutinib | Chronic Lymphocytic Leukemia | 151 | 2023-08-08 | 2027-04-30 | in 253 d | 2026-04-23 |
| NKTX | Nkarta, Inc. | $173M | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNCT05020678Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Phase 1 | Active, not recruiting | Biological: NKX019 | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma | 150 | 2021-08-20 | 2025-03-31actual | — | 2026-04-20 |
| LLY | Eli Lilly and Company | $1.15T | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersNCT07162181Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events | Phase 2 | Active, not recruiting | Drug: Pirtobrutinib | Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma | 13 | 2025-08-07 | May 2030 | ≤ 1,380 d | 2026-04-17 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006Number of participants with treatment-emergent adverse events | Phase 1/2 | Not yet recruiting | Drug: NX-5948, venetoclax, rituximab, obinutuzumab | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 150 | May 2026 | May 2033 | ≤ 2,476 d | 2026-04-13 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)NCT06428019Part 1: Percentage of Participants with Treatment-Emergent Laboratory Tumor Lysis Syndrome (TLS)-Venetoclax | Phase 3 | Recruiting | Drug: Venetoclax, Acalabrutinib, Obinutuzumab | Chronic Lymphocytic Leukemia | 170 | 2024-08-05 | Mar 2028 | ≤ 589 d | 2026-04-09 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) | Phase 3 | Not yet recruiting | Drug: NX-5948, Pirtobrutinib | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 620 | Jun 2026 | Oct 2029 | ≤ 1,168 d | 2026-04-08 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467Objective Response Rate (ORR) | Phase 2 | Recruiting | Drug: APG2575 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 75 | 2021-12-28 | Dec 2026 | ≤ 133 d | 2026-03-27 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNCT04830137Number of Participants with Protocol Specified Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: NX-2127 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL) | 248 | 2021-05-05 | May 2026 | — | 2026-03-20 |
| FATE | Fate Therapeutics | $307M | FT819 in Subjects With B-cell MalignanciesNCT04629729Incidence and nature of dose-limiting toxicities within each dose level cohort | Phase 1 | Active, not recruiting | Drug: FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustine | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia | 54 | 2021-07-12 | 2025-06-18actual | — | 2026-03-19 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508Part A [CLOVER-1] Clinical benefit rate | Phase 2 | Active, not recruiting | Drug: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose | Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | 120 | 2017-07-26 | 2026-06-22 | — | 2026-03-18 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibNCT06876649Percentage of Participants with a Grade ≥3 treatment-emergent AEs | Phase 4 | Recruiting | Drug: Pirtobrutinib | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 787 | 2025-05-20 | May 2030 | ≤ 1,380 d | 2026-03-02 |
| LLY | Eli Lilly and Company | $1.15T | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaNCT06876662Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs) | Phase 4 | Recruiting | Drug: Pirtobrutinib | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 279 | 2025-05-20 | May 2030 | ≤ 1,380 d | 2026-03-02 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)NCT04895436Overall response (OR) in Cohort 1 after end of combination treatment | Phase 2 | Recruiting | Drug: Venetoclax, Obinutuzumab | Chronic Lymphocytic Leukemia (CLL) | 75 | 2022-03-28 | Nov 2026 | ≤ 102 d | 2026-02-09 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)NCT04849416results2024-07-16Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee | Phase 2 | Completed | Drug: LOXO-305 | Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell | 87 | 2021-05-14 | 2023-04-10actual | — | 2026-02-06 |
| INCY | Incyte Corporation | $24.7B | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)NCT04809467results2026-01-29Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) | Phase 1/2 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: tafasitamab, parsaclisib | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 54 | 2021-09-16 | 2024-10-22actual | — | 2026-02-04 |
| ABBV | AbbVie | $457.5B | Expanded Access to VenetoclaxNCT03123029expanded access | — | Available | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia | — | — | — | — | 2026-01-30 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesNCT05665530Dose limiting toxicity (DLT) of PRT2527 | Phase 1 | Completed | Drug: PRT2527, Zanubrutinib, Venetoclax | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | 86 | 2023-09-12 | 2025-06-12actual | — | 2026-01-26 |
| BMY | Bristol-Myers Squibb | $134.9B | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyNCT06357754observationalParticipant in situ hybridization (ISH) or droplet-based digital Polymerase chain reaction (ddPCR) transgene testing results | — | Recruiting | Biological: Idecabtagene vicleucel, Lisocabtagene maraleucel | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma | 50 | 2023-10-06 | 2038-10-06 | in 4,430 d | 2026-01-22 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)NCT05512390Number of Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: ABBV-319 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 154 | 2023-04-26 | Feb 2027 | ≤ 192 d | 2026-01-16 |
| ABBV | AbbVie | $457.5B | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT06291220Percentage of Participants With Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: Obinutuzumab, ABBV-453 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 4 | 2025-01-27 | Jul 2027 | ≤ 345 d | 2026-01-08 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLNCT04155710Phase I: RP2D (Recommended Phase 2 Dose) | Phase 1 | Completed | Biological: IOV-2001 · Drug: Low dose IL-2, High dose IL-2, IL-2 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 7 | 2020-02-19 | 2024-11-11actual | — | 2025-12-24 |
| AZN | AstraZeneca | — | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsNCT04008706Number of participants with adverse events | Phase 3 | Completed | Drug: Acalabrutinib | Chronic Lymphocytic Leukemia | 552 | 2019-09-17 | 2025-11-04actual | — | 2025-12-01 |
| ABBV | AbbVie | $457.5B | A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanNCT06362044observationalPercentage of Participants with Undetectable Minimal Residual Disease (uMRD) | — | Completed | — | Chronic Lymphocytic Leukemia | 89 | 2023-06-07 | 2024-12-31actual | — | 2025-11-25 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05105841Complete Remission (CR) with an Incomplete Marrow Recovery (CRi) Rate, as Assessed by an Independent Review Committee (IRC) per Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) for Venetoclax + Obinutuzumab (V+G) | Phase 2 | Completed | Drug: Venetoclax, Ibrutinib, Obinutuzumab | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 20 | 2021-11-08 | 2025-10-09actual | — | 2025-10-15 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesNCT02290951Safety/overall frequency of adverse events (AEs) | Phase 1 | Completed | Drug: Odronextamab multiple dose levels, Odronextamab multiple dose levels | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 200 | 2015-01-09 | 2025-08-21actual | — | 2025-10-10 |
| SANA | Sana Biotechnology | $1.1B | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)NCT05878184Evaluate safety and tolerability of SC291 | Phase 1 | Active, not recruiting | Drug: SC291 | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 16 | 2023-05-02 | 2025-11-04 | — | 2025-10-02 |
| ABBV | AbbVie | $457.5B | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in GreeceNCT04159779observationalOverall Response Rate (ORR) | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 180 | 2020-01-13 | 2026-06-30 | — | 2025-07-17 |
| BMEA | Biomea Fusion Inc. | $98M | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4) | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2022-01-24 | 2025-02-13actual | — | 2025-07-03 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United KingdomNCT05555979observationalNumber of Participants with a Change in Chronic Lymphocytic Leukemia (CLL) Symptoms | — | Completed | — | Chronic Lymphocytic Leukemia | 56 | 2022-12-14 | 2024-04-10actual | — | 2025-06-29 |
| AZN | AstraZeneca | — | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT06839872Objective Response Rate (ORR) in participants with CLL/SLL. | Phase 2 | Withdrawnsponsor's stated reason: AstraZeneca has made the decision to cancel the trial. | Drug: Pirtobrutinib, Acalabrutinib | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 0 | 2025-06-30 | 2028-07-28 | in 708 d | 2025-06-05 |
| AZN | AstraZeneca | — | MEOI and HRQoL in CLL Patients Treated With BTKisNCT04938141observationalPatient Characteristics | — | Completed | — | Chronic Lymphocytic Leukemia | 23 | 2021-10-07 | 2024-09-26actual | — | 2025-05-21 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLNCT04494503Adverse events of APG-2575 single agent | Phase 1/2 | Recruiting | Drug: APG-2575, Rituximab, Ibrutinib | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 123 | 2020-08-31 | 2024-10-20actual | — | 2025-04-16 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLNCT04215809Primary Toxicity Endpoint: dose limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: Lisaftoclax | CLL/SLL | 144 | 2020-03-02 | 2025-10-31 | — | 2025-04-10 |
| APRE | Aprea Therapeutics | $8M | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)NCT04419389results2024-11-15To Determine the DLT of APR-246 in Combination With Acalabrutinib or in Combination With Venetoclax + Rituximab Therapy in Subjects With NHL, Including Subjects With R/R CLL, RT and R/R MCL. | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 1 | 2021-03-02 | 2021-08-23actual | — | 2025-03-17 |
| APTOF | Aptose Biosciences Inc. | — | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasNCT03893682Incidence of treatment-emergent adverse events of CG-806 | Phase 1 | Terminatedsponsor's stated reason: Change in corporate strategy | Drug: CG-806 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma | 36 | 2019-04-30 | 2024-05-17actual | — | 2025-03-07 |
| BPTH | Bio-Path Holdings, Inc. | $2M | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNCT04072458Identify Dose Limiting Toxicity (DLT) of BP1002 | Phase 1 | Active, not recruiting | Drug: L-Bcl-2 antisense oligonucleotide | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL | 30 | 2020-11-05 | Apr 2025 | — | 2025-02-24 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311results2024-05-07Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria | Phase 3 | Terminatedsponsor's stated reason: Strategic/Business decision | Biological: Obinutuzumab, Ublituximab · Drug: TGR-1202, Chlorambucil | Chronic Lymphocytic Leukemia | 603 | 2015-11-19 | 2023-02-22actual | — | 2024-12-13 |
| XNCR | Xencor, Inc. | $1.9B | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesNCT02924402Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb13676 | B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | 154 | Oct 2016 | Apr 2024actual | — | 2024-11-13 |
| ABBV | AbbVie | $457.5B | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyNCT03406156results2022-11-03Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period) | Phase 3 | Completed | Drug: Obinutuzumab, Bendamustine, Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 120 | 2018-08-10 | 2021-10-12actual | — | 2024-08-06 |
| ADPT | Adaptive Biotechnologies | $3.9B | The clonoSEQ® Watch RegistryNCT04545333observationalDistribution of timepoints at which MRD is monitored using the clonoSEQ Assay in lymphoid malignancy patients in real world settings | — | Terminatedsponsor's stated reason: Sufficient data collected. | Diagnostic test: clonoSEQ Assay | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 465 | 2020-10-13 | 2023-10-01actual | — | 2024-08-01 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04806035RP2D | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: TG-1801, Ublituximab | CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL | 21 | 2021-04-28 | 2024-06-12actual | — | 2024-07-31 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesNCT03671590Maximum Tolerated Dose acceptable for participants | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: TG-1701, Umbralisib · Biological: Ublituximab | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 172 | 2018-09-10 | 2024-05-21actual | — | 2024-07-19 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyNCT02742090results2024-07-03Progression-free Survival | Phase 2 | Terminatedsponsor's stated reason: (Strategic/Business Decision) | Drug: Umbralisib | Chronic Lymphocytic Leukemia | 51 | 2016-04-21 | 2021-06-10actual | — | 2024-07-03 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaNCT00457782To determine Safety & Tolerability by adverse event rates in order to determine recommended Phase II dose | Phase 1 | Completed | Drug: KW-2478 | Multiple Myeloma, Chronic Lymphocytic Leukaemia, B-cell Non-Hodgkin's Lymphoma | 27 | Apr 2007 | Aug 2010actual | — | 2024-04-25 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525results2024-04-19Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria | Phase 2/3 | Terminatedsponsor's stated reason: Strategic/Business decision | Drug: Ublituximab, Umbralisib, Venetoclax | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 277 | 2019-05-16 | 2022-12-20actual | — | 2024-04-19 |
| AZN | AstraZeneca | — | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaNCT04964908observationalTo describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients | — | Completed | — | Chronic Lymphocytic Leukemia | 1,088 | 2021-12-03 | 2023-08-31actual | — | 2024-02-20 |
| PRLD | Prelude Therapeutics | $459M | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesNCT05107856Dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: PRT1419, Azacitidine, Venetoclax | Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma | 21 | 2022-03-22 | 2024-01-19actual | — | 2024-01-31 |
| FATE | Fate Therapeutics | $307M | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesNCT04245722Incidence of dose-limiting toxicities within each dose level cohort | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor. | Drug: FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | 98 | 2020-03-19 | 2023-09-27actual | — | 2023-10-26 |
| ABBV | AbbVie | $457.5B | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeNCT03659669observationalOverall Response Rate (ORR) | — | Suspendedsponsor's stated reason: Strategic considerations | — | Chronic Lymphocytic Leukemia (CLL) | 272 | 2019-02-10 | 2027-02-28 | in 192 d | 2023-10-23 |
| ABBV | AbbVie | $457.5B | A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)NCT04198415observationalNumber of Participants With Adverse Events | — | Completed | — | Cancer, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | 4 | 2020-02-03 | 2022-10-21actual | — | 2023-10-19 |
| ABBV | AbbVie | $457.5B | A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian FederationNCT03873857observationalObjective Response Rate (ORR) 12 Months after Treatment Initiation | — | Completed | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Cancer | 71 | 2019-02-25 | 2022-09-12actual | — | 2023-09-01 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805results2023-07-24Rate of Undetected Minimal Residual Disease (U-MRD) | Phase 2 | Terminatedsponsor's stated reason: Strategic/Business decision | Drug: Ublituximab, Umbralisib, Ibrutinib, Venetoclax, Acalabrutinib Oral Capsule | Chronic Lymphocytic Leukemia | 41 | 2019-08-05 | 2022-05-22actual | — | 2023-07-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05244070Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed. | Drug: BMS-986403, Fludarabine, Cyclophosphamide | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma | 5 | 2022-09-14 | 2023-05-04actual | — | 2023-07-18 |
| EXEL | Exelixis | $13.2B | Study of XL114 in Subjects With Non-Hodgkin's LymphomaNCT05144347Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114 | Phase 1 | Terminatedsponsor's stated reason: Due to Sponsor reasons. | Drug: XL114 | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 2 | 2022-04-12 | 2022-11-01actual | — | 2023-07-11 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304NCT02656303results2023-06-22Overall Response Rate (ORR) as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria | Phase 2 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: Ublituximab · Drug: Umbralisib | Chronic Lymphocytic Leukemia | 116 | 2016-01-07 | 2022-05-26actual | — | 2023-06-22 |
| ABBV | AbbVie | $457.5B | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT00481091results2023-06-13Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) | Phase 1/2 | Completed | Drug: ABT-263 | Chronic Lymphocytic Leukemia | 60 | 2007-07-25 | 2022-05-12actual | — | 2023-06-13 |
| ABBV | AbbVie | $457.5B | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaNCT01682616Assess the safety profile, to determine the maximum tolerated dose and Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab (R) in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. | Phase 1 | Completed | Drug: ABT-199, Rituximab | Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia | 49 | 2012-07-25 | 2022-06-23actual | — | 2023-06-06 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)NCT02756611results2020-05-04Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis | Phase 3 | Completed | Drug: Venetoclax | Chronic Lymphocytic Leukemia | 258 | 2016-06-22 | 2019-04-10actual | — | 2023-04-10 |
| ABBV | AbbVie | $457.5B | Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeNCT03310190observationalDuration of Prophylactic Hospitalization | — | Completed | — | Chronic Lymphocytic Leukemia | 93 | 2018-01-10 | 2022-04-30actual | — | 2023-03-30 |
| ABBV | AbbVie | $457.5B | A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).NCT02980731results2023-02-22Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) | Phase 3 | Completed | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL) | 210 | 2016-12-13 | 2021-12-29actual | — | 2023-02-22 |
| DTIL | Precision BioSciences, Inc. | $227M | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLNCT04030195results2023-01-31Maximum Tolerated Dose (MTD) | Phase 1/2 | Completed | Genetic: PBCAR20A · Drug: Fludarabine, Cyclophosphamide | Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma | 18 | 2020-03-24 | 2021-06-24actual | — | 2023-01-31 |
| ABBV | AbbVie | $457.5B | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyNCT02141282results2022-12-19Overall Response Rate (ORR) | Phase 2 | Completed | Drug: Venetoclax | Chronic Lymphocytic Leukemia | 127 | 2014-09-10 | 2021-12-22actual | — | 2022-12-19 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT01647971Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Phase 1/2 | Completed | Drug: Ublituximab | Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma | 39 | 2012-07-19 | May 2015actual | — | 2022-11-21 |
| ABBV | AbbVie | $457.5B | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaNCT04655261observationalPercentage of Participants Achieving Overall Response Rate (ORR) Best Response | — | Terminatedsponsor's stated reason: Lack of Recruitment | — | Chronic Lymphocytic Leukemia (CLL) | 5 | 2020-12-12 | 2021-11-09actual | — | 2022-10-26 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Ublituximab + Ibrutinib in Select B-cell MalignanciesNCT02013128To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies | Phase 1/2 | Completed | Drug: Ublituximab, Ibrutinib | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 66 | 2014-01-06 | Dec 2015actual | — | 2022-10-24 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationNCT02535286Determine Acceptable Adverse Events That Are Related to Treatment | Phase 1 | Completed | Drug: Umbralisib · Biological: ublituximab, TG-1501 | Chronic Lymphocytic Leukemia, Richter Syndrome | 27 | 2015-09-18 | 2021-11-04actual | — | 2022-10-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLNCT03379051Determine Acceptable Adverse Events That Are Related to Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: Venetoclax, Umbralisib, Lenalidomide · Biological: Ublituximab | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 78 | 2018-03-27 | 2022-05-26actual | — | 2022-08-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Chronic Lymphocytic Leukemia is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Lymphocytic Leukaemia
- CLL
- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic, Chronic, B-Cell
- CLL/SLL
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Chronic Lymphocytic Leukemia” (a text search, wider than this page)